611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Women's Health
Basic InformationLatest News
Why Are Cases of Pancreatic Cancer Rising in Young Women?Depression, Anxiety Could Raise a Pregnant Woman's Odds for C-SectionStill Too Few Women in Stroke Treatment Clinical TrialsMore Middle-Aged, Older Women Getting  'Broken Heart' SyndromePregnancy, Delivery Safe for Women Born With Heart DefectsFDA Warns Against Using At-Home Dermal Filler 'Pens'AHA News: Broken Heart Syndrome Is on the Rise, Especially Among Older WomenLengthening Menstrual Cycles Near Menopause Could Predict Heart HealthAI Helps Rule Out Cancer in Women With Dense BreastsPandemic Stress Altered Many Women's Menstrual CyclesBreastfeeding Longer May Lower Postpartum Depression RiskAHA News: How Black Women Can Take Control of Their Blood PressureLow-Dose Aspirin Guards Against Preeclampsia: Task ForceCan a Computer Program Help Docs Spot Breast Cancer?Diabetes Drug Might Help Women With Preeclampsia Prolong Their PregnancyCommon Hormone Disorder in Women Costs U.S. $8 Billion a YearSexual Assault Could Affect a Woman's Long-Term Brain HealthMigraines and More Severe Hot Flashes Could Be LinkedMore Women Turning to Marijuana Products to Help With MenopauseDepression During Menopause: How to Spot It and Treat ItPandemic Has Many Women Holding Back on Motherhood, NYC Study FindsIs Hysterectomy Always Needed for a Common, Painful Gynecologic Condition?Your State's Laws Might Save Your Life If Breast Cancer StrikesMom-to-Be's 'Leaky' Heart Valves May Pose More Danger Than ThoughtMore College-Educated Women Are Having Children Outside of MarriageAI May Not Be Ready to Accurately Read MammogramsPandemic Brought Big Drop in Breast Cancer Screening in Older, Low-Income WomenWomen May Find It Tougher to Quit Smoking Than MenFor Better Breastfeeding, 'Lactation Consultants' Can HelpCOVID Vaccine Safe, Recommended for Pregnant Women, CDC SaysCould Women's Health Decline Along With Their Height?Women Less Likely to Get Best Care for Deadly Form of StrokeHRT Could Raise Odds for AsthmaLeading U.S. Ob-Gyn Groups Urge COVID Vaccines for All Pregnant WomenAcne Can Take Big Emotional Toll on WomenVitamin D May Lower Black Women's Odds for COVID-19Mom's Weight-Loss Surgery Lowers Many Pregnancy Complications, Raises OthersPregnant Women Need to Take Care in Sweltering Summer HeatAre Antibiotics Really the Answer for UTIs in Women?Stronger Hearts, Better Outcomes in Pregnancy: StudyCould Menopausal Hormone Therapy Reduce Women's Odds for Dementia?Screening Often Misses Endometrial Cancer in Black WomenAHA News: Pregnant Mom's Diet May Influence Baby's Cardiovascular HealthPandemic Delays in Screening Mean More Breast Cancer Deaths Ahead: StudyUrinary Incontinence Can Affect a Woman's Mental HealthCOVID Vaccine Doesn't Infiltrate Breast MilkGap in Breast Cancer Survival for Black, White Patients Shrinks, But Not by EnoughCost a Barrier to Cervical Cancer Screening for Many U.S. WomenAlcohol Still a Threat in Too Many American Pregnancies: StudyWomen's Cancer Screenings Plummeted During Pandemic
Questions and AnswersLinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Wellness and Personal Development
Mental Disorders

Drug Lynparza Could Help Fight Some Early-Stage Breast Cancers

HealthDay News
by By Dennis Thompson HealthDay Reporter
Updated: Jun 4th 2021

new article illustration

FRIDAY, June 4, 2021 (HealthDay News) -- A twice-daily pill can dramatically reduce the risk of breast cancer recurrence in women who are genetically prone to the disease, researchers report.

The pill — olaparib (Lynparza) — works by blocking a natural enzyme called PARP that normally fixes DNA damage in healthy cells, but in these women actually promotes the growth of cancerous cells.

Early high-risk breast cancer patients taking olaparib for a year had a 42% reduced risk of cancer recurrence or death compared to those given a placebo, said lead researcher Dr. Andrew Tutt, director of the Breast Cancer Now Toby Robins Research Center at the Institute of Cancer Research in London.

"Patients who received olaparib after surgery and chemotherapy were more likely to be alive without cancer and avoid metastasis than the patients who received placebo," he said.

These results were presented Thursday at an online meeting of the American Society of Clinical Oncology. Findings presented at meetings should be considered preliminary until published in a peer-reviewed journal.

Olaparib already is approved to treat patients with metastatic breast cancer who have mutations in the BRCA1 or BRCA2 genes. These genes typically suppress cancer, but mutations actually increase cancer risk for some people.

About 5% of breast cancers are associated with BRCA1 or BRCA2 mutations, Tutt noted.

Breast cancers that occur due to BRCA1 or BRCA2 mutations rely on the PARP enzyme to remain alive, grow and divide. Drugs called PARP inhibitors take advantage of this fact to block the enzyme and prevent the cancer from coming back.

In this clinical trial, more than 1,800 patients with stage 2 to 3 breast cancers treated with surgery and chemotherapy were randomly assigned to take either 300 milligrams of olaparib or a placebo twice a day for a year.

Patients on olaparib had a three-year invasive disease-free survival rate — no recurring breast cancer or other new cancers — of about 86%, compared with 77% for those taking a placebo, the findings showed.

Dr. Amy Tiersten is a professor of hematology and medical oncology with the Icahn School of Medicine at Mount Sinai in New York City. She said, "We have already known for some time that PARP inhibitors have activity in patients with metastatic breast cancer, but this is the first time we have seen efficacy in the early-stage setting. This study showed a substantial reduction in the risk of recurrence in this population and, therefore, the potential to cure more patients with BRCA-associated early breast cancer."

Side effects were consistent with previous studies of olaparib, Tutt said. The most serious common side effects included anemia, lower white blood cell counts and fatigue.

Tutt said the study shows the importance of performing genetic testing on cancer patients, to look for traits and mutations that could be exploited to improve treatment and survival.

"There certainly is a case for a mindset change in the community around where we use germline genetic testing," Tutt said. "We've classically thought about it as something to do to determine someone's risk of the disease and inform perhaps other members of their family if they've already had it."

Instead of just assessing risk, this genetic information can be used to save lives, Tutt noted.

Dr. Lori Pierce, president of the American Society of Clinical Oncology, agreed.

"This further highlights the importance of genetic testing in appropriate patients so that we know which patients will benefit from this therapy," Pierce said. "I think it may even open the door to additional trials of adjuvant PARP inhibitors for other BRCA1- and 2-associated cancers."

Olaparib can be a pricey drug. The cost for a supply of sixty 100-milligram tablets is a little more than $7,500, according to Drugs.com.

More information

Dana-Farber Cancer Institute has more about PARP inhibitors.

SOURCES: Andrew Tutt, MBChB, PhD, director, Breast Cancer Now Toby Robins Research Center, Institute of Cancer Research, London; Lori Pierce, MD, president, American Society of Clinical Oncology, Alexandria, Va.; Amy Tiersten, MD, professor, hematology and medical oncology, Icahn School of Medicine at Mount Sinai, New York City; presentation, American Society of Clinical Oncology, June 3, 2021, online